PRESS RELEASE published on 02/12/2025 at 07:30, 11 months 21 days ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats à 5 ans de la thérapie génique LUMEVOQ® pour la NOHL, confirmant l'efficacité durable et le profil de sécurité favorable Sécurité Efficacité Thérapie Génique GenSight Biologics LUMEVOQ
BRIEF published on 01/23/2025 at 18:50, 1 year ago GenSight Biologics : Bilan Financier et Perspectives GenSight Biologics LUMEVOQ® Augmentations De Capital Accès Compassionnel Trésorerie 2024
BRIEF published on 01/23/2025 at 18:50, 1 year ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation financière 2024 et donne des mises à jour sur ses activités, y compris le financement et la progression réglementaire de LUMEVOQ. La trésorerie s'élève à 2,5M€ à fin 2024 Financement Trésorerie Situation Financière GenSight Biologics LUMEVOQ
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year ago GenSight Biologics publie les résultats à long terme de LUMEVOQ® Thérapie Génique GenSight Biologics LUMEVOQ® Acuité Visuelle Neuropathie Optique Héréditaire De Leber
BRIEF published on 01/15/2025 at 07:35, 1 year ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats cliniques à 5 ans de la thérapie génique LUMEVOQ chez les patients atteints de NOHL, démontrant une amélioration bilatérale de l'acuité visuelle et un profil de sécurité favorable Thérapie Génique GenSight Biologics NOHL LUMEVOQ Résultats Cliniques
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
Published on 02/06/2026 at 03:50, 2 hours 35 minutes ago High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 02:45, 3 hours 40 minutes ago High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 00:57, 5 hours 28 minutes ago Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 6 hours 25 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 7 hours 10 minutes ago Amarc Further Expands Its Toodoggone Technical Team
Published on 02/06/2026 at 06:05, 20 minutes ago Driven by Chairman Junhyuk Bang's Visionary Leadership, Coway Announces Financial Results for Q4 and FY2025
Published on 02/06/2026 at 05:50, 35 minutes ago CGTN: Xi Jinping's same-day calls with Putin and Trump underscore China's role in global stability
Published on 02/05/2026 at 19:27, 10 hours 57 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 11 hours 39 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 12 hours 16 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 19:15, 11 hours 10 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 11 hours 10 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 11 hours 10 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
